Overseas CXO/ life science upstream 2Q24 review: life science upstream continuing to expect demand recovery
GAC Group (2238 HK) We expect 4Q22 NP to fall on equity income
Weak 1Q23 as expected; Expect multiple drivers from iPhone/CPU socket/400G/EV in 2H23E
3Q24 earnings below expectations due to margin contraction
–Expect steady 3Q23 despite macro uncertainty
–Expecting a sequential recovery in 4Q
ESOP targets stabilize earnings expectation but sentiment overhang remains
1H23E preview: Expect profit decline on weak coal price
China's Economy:Money and Credit Growth Beats Expectations; the Central Bank might Slightly Rein in Its Pace of Monetary Loosening
Expecting a solid 1H23